Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at da...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Crit Care Explor
Hlavní autoři: Rajendram, Prabalini, Sacha, Gretchen L., Mehkri, Omar, Wang, Xiaofeng, Han, Xiaozhen, Vachharajani, Vidula, Duggal, Abhijit
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2021
Témata:
Observational Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7808529/
https://ncbi.nlm.nih.gov/pubmed/33490955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCE.0000000000000327
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky